The Family Stone (2005): A Recurrence at Christmas

Everett Stone brings his rigid, over-controlled girlfriend Meredith home to the family's New England house for Christmas. He intends to propose with his mother's heirloom ring. The Stones are bohemian, loud and tightly bonded, and they take against her instantly. A series of escalating humiliations follows, culminating in a disastrous argument at dinner about Everett's deaf gay brother Thad and his partner.

Meredith summons her easier-going sister Julie. Everett is drawn to Julie, and Meredith ends up drunk and then in bed with Everett's brother Ben.

Underneath the farce is the reason Sybil grips her family so hard. Her breast cancer has returned and is terminal. She has told her husband Kelly, and in one quiet scene Kelly tells Ben. Sybil never delivers a diagnosis speech. The film then jumps a year. The couples have rearranged themselves, and Sybil has died.

Spoilers throughout. This page says how The Family Stone ends.

The film's best decision is that Sybil does not announce anything. The audience learns second-hand, from her husband, in a kitchen, badly. Information is rationed. The ill person protects everyone else by saying nothing.

Her intensity about who her children marry reads as ordinary snobbery until the reason arrives. That is a sharp observation about how the dying get misread. Skipping to a Christmas without her, with no death scene, is honest about how absence actually registers.

The film never says where. That single omission removes almost everything a team would work from.

Recurrence divides at the start. Locoregional recurrence returns in the breast, the chest wall or nearby lymph nodes. Distant recurrence has reached another organ. NCI reports that locoregional rates have fallen over time. A meta-analysis suggests under 3% after breast-conserving surgery with radiation. After mastectomy the figure is up to 10%. And between 9% and 25% of people with a locoregional recurrence already have distant metastases, or locally extensive disease, when it is found.

So "it came back" is not one situation. It is at least two, with different treatments and different goals.

NCI states that restaging is indicated before a recurrence is treated. It also says that cell or tissue confirmation of the recurrence is obtained whenever possible. In plain terms: image it, then biopsy it, then decide.

The receptors get re-checked too. Estrogen receptor, progesterone receptor and HER2 status at the time of recurrence all feed the choice of therapy. So does the earlier treatment. NCI notes that receptor status can change. In one small study, 36% of hormone-receptor-positive tumors were receptor-negative when biopsied at recurrence. A tumor that was receptor-positive years ago may not be now.

On the goal, NCI is direct. Recurrent breast cancer often responds to therapy, although treatment is rarely curative at that stage. People with a locoregional recurrence may still become long-term survivors with appropriate therapy.

NCI's summary sorts treatment for a locoregional recurrence by site.

• Chest wall after mastectomy. Often a sign of wider disease. In a subset it is the only site, and surgery or radiation may still be curative.
• Chest wall recurrences under 3 cm carry the best chance of prolonged survival. So do axillary or internal mammary node recurrences, rather than supraclavicular ones. So does a gap of more than 2 years before the cancer returned.
• Breast, after earlier conservation. Further local treatment such as mastectomy is considered.

Systemic therapy is considered as well. The CALOR trial tested this. People whose isolated local recurrence had been fully removed were assigned to chemotherapy or none. It closed early with 162 enrolled. In receptor-negative disease, chemotherapy won clearly. Ten-year disease-free survival was 70%, against 34%. In receptor-positive disease it did not help.

That is why the receptor result matters so much. It decides whether chemotherapy after removal is worth its cost.

Mammography exists to find a first breast cancer in someone with no symptoms. The USPSTF recommends a screening mammogram every 2 years for women aged 40 to 74. That is a grade B recommendation. The task force concludes with moderate certainty that the net benefit is moderate. For women 75 and older it rates the evidence insufficient. It does the same for extra ultrasound or MRI in women with dense breasts. Grade I means unresolved, not negative.

None of that is the mechanism that finds a recurrence. That comes from follow-up appointments, and from symptoms someone reports between them. See cancer screening for what population screening is designed to do.

Sybil has no hair loss, no fatigue, no appointments, no medication and no visible symptoms. She cooks, hosts and argues at full strength. There is no oncology, no palliative care, and no sign that a treatment decision was ever made. Her death happens entirely between scenes.

As drama that is defensible. As information it leaves a viewer with nothing. Treatment for recurrent disease is often continuous. It is measured in years, not in cycles.

Cancer Explained has no advertisers and nothing to sell. Reader support is what keeps it open to anyone who lands on it. Support our work.

The Family Stone is a film about a family, with a cancer inside it that is never opened. The useful correction is narrow. "It came back" is the start of a set of questions — where, how far, which receptors now — and not the end of one.

• NCI — Breast Cancer Treatment (PDQ®), Health Professional Version
• USPSTF — Breast Cancer: Screening (2024)

This page discusses The Family Stone for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care. Spotted an error? Please email [email protected].